Main Article Content
Abstract
Summary: combined oral contraceptives (COCs) are not only highly effective way to protect against unwanted pregnancy, but also a means of regulating the menstrual cycle, prevention and treatment of a whole group of gynecological diseases. Thanks to advances in science of the last decades, the choice of contraceptive methods unusually extended, was made possible by the transition to a high dose COCs and micro-dose drugs. Despite the fact that not all aspects of the effects of COCs sufficiently explored, is generally recognized key role in their family planning programs. In recent years, the problem has acquired special urgency regulation of reproductive function in women with extragenital pathology.
Objective: To evaluate the current position of the use of combined oral contraceptives for the treatment of various gynecological diseases.
Materials and Methods: provides an overview of the literature devoted to the assessment of the prevalence of the use of COCs, the modern concept of the mechanism of action and approaches to their destination.
Results: the diversity of the clinical action of COCs allows to consider their drugs of first choice for protection against unwanted pregnancy, as well as the method of treatment of gynecological diseases, such as menstrual disorders, the elimination or reduction in the severity of dysmenorrhea, reduction of symptoms in premenstrual syndrome, reducing the frequency of inflammatory diseases of small bodies pelvis etc. After using COCs reduces the risk of cancer of the endometrium, ovaries and mammary glands.
Conclusion: The correct and timely appointment of combined oral contraceptives not only eliminates the risk of unwanted pregnancies, but also provides a therapeutic effect in various gynecological diseases.Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Armstrong AJ et al. Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol. 2012; 19 (5): 562-571
Baranov II. Combined oral contraceptives: principles of individual selection, prevention of unwanted pregnancy and possible side effects, therapeutic and prophylactic action. Russkij medicinskij zhurnal. 2013; 21 (14): 745-750. Russian (Баранов И.И. Комбинированные оральные контрацептивы: принципы индивидуального подбора, предупреждение нежелательной беременности и возможных побочных эффектов, лечебное и профилактическое действие //РМЖ. 2013. № 14. С. 745-750.)
Colonna L, Pacifico V, Lello S, Sorge R, Raskovic D, Primavera G. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation. J Eur Acad Dermatol Venerol. 2011. doi: 10.1111/j.1468-3083.2011.04292.x
Dedov II, Mel'nichenko GA, Chebotnikova TV, Il'in AV, Davydova GN, Kolesnikova GS, Ivannikova EV. The prevalence and clinical features of polycystic ovary syndrome in a Moscow population. Problems of Endocrinology. 2010. 56 (4): 3-8. Russian (Дедов И.И., Мельниченко Г.А., Чеботникова Т.В., Ильин А.В., Давыдова Г.Н., Колесникова Г.С., Иванникова Е.В. Распространенность и клиническая картина синдрома поликистозных яичников в популяции Москвы //Проблемы эндокринологии. 2010. Т. 56, № 4. С. 3-8.)
Edith Vaisberg. Choices method of contraception: combined oral contraceptives. The University of Sydney NSW Australia. 2014. P. 12-14
Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. Emergency Contraception update. J of Family Planning and Reproductive Health Care. 2011; 32 (2): 34-37
Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: aran – domized, double-blind, activecontrolled, parallel-group, US-based, multicenter study. Sr. S. Bart. Contraception. 2012; 85 (1): 42-50
Gevorgian МА, Manukhin IB, Kuznetsova EM. Experience with drospirenone containing hormonal contraceptive. Russkij medicinskij zhurnal. 2011; (1): 22-24. Russian (Геворкян М.А., Манухин И.Б., Кузнецова Е.М. Опыт применения дроспиренонсодержащего гормонального контрацептива //РМЖ. 2011. № 1. С. 22-24.)
Khamoshina MB, Nosova AV, Zorina EA. Impact of combined oral contraceptive containing Estradiol Valerate on female quality of life. Doktor.Ru. 2012; (1): 33-36. Russian (Хамошина М.Б., Носова А.В., Зорина Е.А. Влияние комбинированного орального контрацептива, содержащего эстрадиола валерат, на качество жизни женщин //Доктор.Ру. 2012. № 1. С. 33-36.)
Khamoshina MB, Savelieva IS, Tsapieva EO, Zorina EA. Hormonal contraception without ethinylestradiol: hopes, potentials and prospects. Doktor.Ru. 2011; 9-2 (68): 15-20. Russian (Хамошина М.Б., Савельева И.С., Цапиева Е.О., Зорина Е.А. Гормональная контрацепция без этинилэстрадиола: ожидания, возможности, перспективы //Доктор.Ру. 2011. № 9-2 (68). С. 15-20.)
Landrum LM, Zuna RE, Walker JL. Endometrial Hyperplasia, Estrogen Therapy and the Prevention of Endometrial Cancer. Clinical Gynecologic Oncology. Eight edition /Di Saia PJ, Creasman WT: Elsiver, 2012; 123-129
Lopez-del Burgo C. Women’s attitudes towards mechanisms of action of birth control methods: a cross sectional study in five European countries. J. of Clinical Nursing. 2013; (22): 3006-3015
Machado RB, Pompeil de M, Giribela AG, Giribela CG. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl). 2011; 7 (1): 19-30
Navaratnarajah R, Pillay OC, Hardiman P et al. Polycystic ovary syndrome and endometrial cancer. Semin. Reprod. Med. 2011; 26 (1): 62-71
Potter J., Santelli J.S. Adolescent contraception: review and guidance for pediatric clinicians. Minerva Pediatr. 2015; 67 (1): 33-45.
Pozdnyak SA. Drug therapy for premenstrual syndrome. Obstetrics and Gynecology. 2011; (8): 117-120. Russian (Поздняк А.О. Медикаментозная терапия предменструального синдрома //Акушерство и гинекология. 2011. № 8. С. 117-120.)
Ruzhilo OS Ways to restore menstrual function in polycystic ovary syndrome. UO «Vitebsk State Medical University»: Materials of the 69th scientific session of the University staff. 2014: 175-176. Russian (Ружило О.С. Пути восстановления менструальной функции при синдроме поликистозных яичников. УО «Витебский государственный медицинский университет»: Матер. 69-й науч. сессии сотрудников университета, 2014. С. 175-176.)
Savelieva IS, Khamoshina MB. Post-abortion contraception: whose side are you on? Doktor.Ru. 2011; 9-1 (68): 54-57. Russian (Савельева И.С., Хамошина М.Б. Контрацепция после аборта: на чьей вы стороне? //Доктор.Ру. 2011. № 9-1 (68). С. 54-57.)
Shatunova EP, Stepanova Y. Use of hormonal contraceptives in a rehabilitation program after prior exacerbation of chronic salpingoophoritis. Obstetrics and Gynecology. 2011; (2): 106-110. Russian (Шатунова Е.П., Степанова Ю.В. Применение гормональных контрацептивов в программе реабилитации после перенесенного обострения хронического сальпингоофорита //Акушерство и гинекология. 2011. № 2. С. 106-110.)
Sitruc R, Nath A. Metabolic effects of contraceptive steroids. J. Med. 2011; 12 (2): 63-75
Soboleva EL. The etiology, clinical features and treatment of polycystic ovary syndrome. Disease Treatment and Prevention. 2012; (1): 88-98. Russian (Соболева Е.Л. Этиология, патогенез, клиника и лечение синдрома поликистозных яичников //Лечение и профилактика. 2012. № 1. С. 88-98.)
Therapeutic potential of modern oral contraceptives in gynecological practice. Effective pharmacotherapy. 2011; (4): 40-46. Russian (Лечебные возможности современной оральной контрацепции в гинекологической практике //Эффективная фармакотерапия. 2011. № 4. С. 40-46.)
Tikhomirov AL, Bataeva AE. Evolution of combined hormonal contraception. Gynecology, obstetrics and perinatology. 2011; 10 (4): 71-75. Russian (Тихомиров А.Л., Батаева А.Е. Эволюция комбинированной гормональной контрацепции //Вопросы гинекологии, акушерства и перинатологии. 2011. Т. 10, № 4. С. 71-75.)
Unanyan AL, Arakelov SE, Polonskaya LS, Guriev TD, Baburin DV, Kossovich YuM. Dysmenorrhea: practical issues of pathogenesis, clinical presentation and treatment. Doktor.Ru. 2014; 1 (89): 15-19. Russian (Унанян А.Л., Аракелов С.Э., Полонская Л.С., Гуриев Т.Д., Бабурин Д.В., Коссович Ю.М. Дисменорея: практические аспекты патогенеза, клиники и терапии //Доктор.Ру. 2014. № 1 (89). С. 15-19.)
Verchaeghe J. Hormonal contraception in women with metabolic syndrome. Contracept. Reprod. Health Care. 2011; 5 (5): 305-314
Zaharova NN, Dvorjansky SA. Results of application of the combined oral contraceptives with drospirenon and finasterid in women with a polycystic ovary syndrome without metabolic infringements. Practical medicine. 2011; 6 (54): 76-79. Russian (Захарова Н.Н., Дворянский С.А. Результаты применения комбинированных оральных контрацептивов с дроспиреноном у женщин с синдромом поликистозных яичников //Практическая медицина. 2011. Т. 54, № 6. С. 76-79.)
Zazerskaya IE, Kuznetsova LV. The use of combined oral contraceptives in the prevention and treatment of endometriosis. Problemy reproduktsii. 2015; 21 (3): 106-110. Russian (Зазерская И.Е., Кузнецова Л.В. Место комбинированных оральных контрацептивов в лечении эндометриоза //Проблемы репродукции. 2015. Т. 21, № 3. С. 106-110.)